ResMed Inc. 10-Q Summary: Period Ended December 31, 1999
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep-disordered breathing. The report covers the three and six months ended December 31, 1999. Principal manufacturing is located in Australia, with distribution in the U.S., U.K., Asia, and Europe.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1999 | Six Months Ended Dec 31, 1999 |
|---|---|---|
| Net Revenue | $28.1 million | $54.1 million |
| Gross Profit | $19.5 million (69% margin) | $37.3 million (69% margin) |
| Operating Income | $8.6 million | $16.0 million |
| Net Income | $5.4 million | $10.2 million |
| Diluted EPS | $0.34 | $0.65 |
| Cash from Operations | N/A | $7.0 million |
| Cash & Equivalents | $11.5 million (Balance Sheet) | $11.5 million (Balance Sheet) |
| Working Capital | $41.6 million | $41.6 million |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 31% ($6.6M) for the quarter and 33% ($13.4M) for the six months compared to the prior year periods. Growth was driven by increased unit sales of flow generators and accessories in America, Europe, and Asia Pacific.
- Profitability: Gross profit margins improved from 68% to 69% due to a shift in geographical sales mix and better manufacturing capacity utilization.
- Expenses: Selling, general, and administrative (SG&A) expenses rose 30% ($2.1M) for the quarter, primarily due to an increase in sales and administrative personnel (from 185 to 239) and IT investments. R&D expenses increased 20% ($0.3M) for the quarter due to new product development.
- Cash Flow: Net cash provided by operating activities decreased to $7.0 million for the six months ended Dec 31, 1999, from $9.2 million in the prior year, largely due to increased inventory and receivables balances.
- Foreign Exchange: Other income (expense) net showed a loss of $302,000 for the quarter, an increase in loss compared to the prior year, primarily due to higher net foreign exchange losses.
Outlook, Risks, and Contingencies
- Legal Proceedings: The Company is engaged in ongoing patent litigation with Respironics in the U.S. and Australia. In the U.S., the Court has granted three partial summary judgment motions for non-infringement; ResMed intends to appeal. In Australia, Respironics alleges unfair trade practices seeking approximately $1.0 million in damages. The Company is incurring ongoing legal costs.
- Market Risk: The Company faces foreign currency risk due to Australian manufacturing and international sales. It utilizes foreign currency option contracts (notional amount of $119 million as of Dec 31, 1999) to hedge these exposures.
- Accounting Changes: The Company has not yet determined the impact of SFAS No. 133 (Accounting for Derivative Instruments), effective September 30, 2000.
- Capital Expenditures: Capital spending decreased to $5.6 million for the six months ended Dec 31, 1999, from $10.7 million in the prior year, reflecting the completion of a new manufacturing facility in March 1999.
Investor Verification Checklist
- Verify the status and potential financial impact of the patent litigation with Respironics in both the U.S. and Australia.
- Monitor the effectiveness of foreign currency hedging strategies given the significant exposure to the Australian Dollar and Euro.
- Assess the sustainability of SG&A expense growth relative to revenue as the sales force continues to expand.
- Review inventory levels, which increased significantly ($5.4M cash outflow in six months), to ensure they align with sales demand.
- Confirm the timeline and potential impact of adopting SFAS No. 133 on future financial reporting.